Lancet, Vol. 380, no.9856, p. 1829-39 (2012) Lancet, 380(9856), 1829-1839. Elsevier Science Coles, A J, Twyman, C L, Arnold, D L, Cohen, J A, Confavreux, C, Fox, E J, Hartung, H P, Havrdova, E, Selmaj, K W, Weiner, H L, Miller, T, Fisher, E, Sandbrink, R, Lake, S L, Margolin, D H, Oyuela, P, Barkhof, F, Panzara, M A & Compston, D 2012, ' Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial ', Lancet, vol. 380, no. 9856, pp. 1829-1839 . https://doi.org/10.1016/S0140-6736(12)61768-1 Lancet, 380(9856), 1829-1839. Elsevier Limited
Wolinsky, J S, Confavreux, C, Comi, G, Kappos, L, Olsson, T P, Benzerdjeb, H, Truffinet, P, Wang, L, Miller, A E, Freedman, M S, Stenager, E & Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group 2011, ' Randomized trial of oral teriflunamide for relapsing multiple sclerosis ', The New England Journal of Medicine, vol. 2011, no. 365, pp. 1293-1303 . https://doi.org/10.1056/NEJMoa1014656 New England Journal of Medicine, 365(14), 1293-1303. MASSACHUSETTS MEDICAL SOCIETY
Wolinsky, J S, Narayana, P A, Nelson, F, Datta, S, O'Connor, P, Confavreux, C, Comi, G, Kappos, L, Olsson, T P, Truffinet, P, Wang, L, Miller, A, Freedman, M S, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group & Stenager, E 2013, ' Magnetic resonance imaging outcomes from a phase III trial of teriflunomide ', Multiple sclerosis, vol. 19, no. 10, pp. 1310-1319 . https://doi.org/10.1177/1352458513475723
Journal of the Neurological Sciences, 292(1-2), 28-35. Elsevier Radue, E W, Stuart, W H, Calabresi, P A, Confavreux, C, Galetta, S L, Rudick, R A, Lublin, F D, Weinstock-Guttman, B, Wynn, D R, Fisher, E, Papadopoulou, A, Lynn, F, Panzara, M A, Sandrock, A W, Polman, C H, Zwemmer, J N P, Nielsen, J M & Kragt, J J 2010, ' Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis ', Journal of the Neurological Sciences, vol. 292, no. 1-2, pp. 28-35 . https://doi.org/10.1016/j.jns.2010.02.012